Literature DB >> 2537401

Platelet-activating factor-induced phosphoinositide metabolism in differentiated U-937 cells in culture.

G Barzaghi1, H M Sarau, S Mong.   

Abstract

Human monocytic leukemic U-937 cells, when differentiated with dimethylsulfoxide to macrophage-like state, express receptors for platelet-activating factor (PAF). In the differentiated U-937 cells, PAF induced hydrolysis of phosphoinositides and synthesis of inositol phosphates. PAF-induced production of inositol phosphates was rapid, concentration-dependent and was inhibited by a receptor antagonist CV3988, indicating that it was mediated via a specific receptor. In fura-2-loaded, differentiated U-937 cells, PAF induced immediate and concentration-dependent calcium mobilization [( Ca++]i) that was inhibited by CV3988, but not by calcium channel blockers. Addition of an increasing concentration of calcium chelator, ethylene glycol bis(beta-aminoethyl ether)-N,N'-tetraacetic acid, to the medium inhibited a large fraction (approximately 75%) of PAF receptor-induced [Ca++]i mobilization thus suggesting the majority of [Ca++]i mobilization was originated from extracellular milieu and a small portion (approximately 25%) was originated from intracellular sources. The inositol phosphate production induced by PAF, however, was independent from the extracellular calcium and was not inhibited by the addition of ethylene glycol bis(beta-aminoethyl ether)-N,N'-tetraacetic acid. Neither [Ca++]i mobilization or phosphoinositide metabolism in U-937 cells was sensitive to treatment of pertussis toxin, but both types of effects were sensitive to treatment by an inhibitor of phospholipase C, manoalide. These results suggest that in differentiated U-937 cells PAF receptor is coupled through a pertussis toxin-insensitive guanine nucleotide binding protein to a phosphoinositide specific phospholipase C. Inositol-trisphosphate, and possibly diacylglycerol, could be the intracellular messengers for PAF receptor in U-937 cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537401

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Inositol phospholipid turnover in PAF transmembrane signalling.

Authors:  S D Shukla
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

2.  Effects of Platelet-Activating Factor on Brain Microvascular Endothelial Cells.

Authors:  Eugen Brailoiu; Christine L Barlow; Servio H Ramirez; Mary E Abood; G Cristina Brailoiu
Journal:  Neuroscience       Date:  2018-03-06       Impact factor: 3.590

Review 3.  Platelet-activating factor: receptors and signal transduction.

Authors:  W Chao; M S Olson
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

4.  Intracellular Ca2+, inositol 1,4,5-trisphosphate and additional signalling in the stimulation by platelet-activating factor of prostaglandin E2 formation in P388D1 macrophage-like cells.

Authors:  R Asmis; C Randriamampita; R Y Tsien; E A Dennis
Journal:  Biochem J       Date:  1994-03-15       Impact factor: 3.857

5.  Protein kinase C activator phorbol 12, 13-dibutyrate inhibits platelet activating factor-stimulated Ca2+ mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells.

Authors:  T L Yue; J L Gu; G Feuerstein
Journal:  Neurochem Res       Date:  1992-10       Impact factor: 3.996

6.  Mechanism of endothelin-1 activation of MAP kinases in neonatal pulmonary vascular smooth muscle.

Authors:  Scott A Barman; Mario B Marrero
Journal:  Lung       Date:  2005 Nov-Dec       Impact factor: 2.584

7.  Agonist-induced down-regulation of platelet-activating factor receptor gene expression in U937 cells.

Authors:  L Y Chau; K Peck; H H Yen; J Y Wang
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

8.  Inhibition by the PAF antagonist WEB 2086 of PAF induced inositol-1,4,5-trisphosphate production in human platelets.

Authors:  F W Birke; H A Ensinger
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.